Wednesday, June 10, 2026

Patent intelligence · US

US 10092736

Device and method for dispensing a drug

granted A61PA61P17/00A61P17/02A61P17/06
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 12
Applicant portfolio 308
Patent details — US 10092736
Jurisdiction
US
Status
granted
Grant date
Oct 9, 2018
Expiration
Oct 4, 2038
Applicant
Demira, Inc.
Claims
8
CPC classes
A61P, A61P17/00, A61P17/02, A61P17/06
View on Google Patents ↗

Quick answer

US 10092736 (Device and method for dispensing a drug) is held by Demira, Inc.. Status: granted. Granted Oct 9, 2018. Expires Oct 4, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Demira, Inc.
Grant date
Expiration
Claims
8
CPC classes
A61P, A61P17/00, A61P17/02, A61P17/06, A61P17/10, A61P17/12

More from Demira, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 10092736?

US 10092736 (Device and method for dispensing a drug) is held by Demira, Inc.. Status: granted. Granted Oct 9, 2018. Expires Oct 4, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10092736?

Demira, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 10092736 expire?

Our index shows an expiration date of Oct 4, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.